Carol Wysham, Anuj Bhargava, Louis Chaykin, Raymond de la Rosa, Yehuda Handelsman, Lone N Troelsen, Kajsa Kvist, Paul Norwood. JAMA 2017
Times Cited: 146
Times Cited: 146
Times Cited
Times Co-cited
Similarity
Efficacy and Safety of Degludec versus Glargine in Type 2 Diabetes.
Steven P Marso, Darren K McGuire, Bernard Zinman, Neil R Poulter, Scott S Emerson, Thomas R Pieber, Richard E Pratley, Poul-Martin Haahr, Martin Lange, Kirstine Brown-Frandsen,[...]. N Engl J Med 2017
Steven P Marso, Darren K McGuire, Bernard Zinman, Neil R Poulter, Scott S Emerson, Thomas R Pieber, Richard E Pratley, Poul-Martin Haahr, Martin Lange, Kirstine Brown-Frandsen,[...]. N Engl J Med 2017
71
Effect of Insulin Degludec vs Insulin Glargine U100 on Hypoglycemia in Patients With Type 1 Diabetes: The SWITCH 1 Randomized Clinical Trial.
Wendy Lane, Timothy S Bailey, Gregg Gerety, Janusz Gumprecht, Athena Philis-Tsimikas, Charlotte Thim Hansen, Thor S S Nielsen, Mark Warren. JAMA 2017
Wendy Lane, Timothy S Bailey, Gregg Gerety, Janusz Gumprecht, Athena Philis-Tsimikas, Charlotte Thim Hansen, Thor S S Nielsen, Mark Warren. JAMA 2017
48
Hypoglycaemia risk with insulin degludec compared with insulin glargine in type 2 and type 1 diabetes: a pre-planned meta-analysis of phase 3 trials.
R E Ratner, S C L Gough, C Mathieu, S Del Prato, B Bode, H Mersebach, L Endahl, B Zinman. Diabetes Obes Metab 2013
R E Ratner, S C L Gough, C Mathieu, S Del Prato, B Bode, H Mersebach, L Endahl, B Zinman. Diabetes Obes Metab 2013
40
More Similarities Than Differences Testing Insulin Glargine 300 Units/mL Versus Insulin Degludec 100 Units/mL in Insulin-Naive Type 2 Diabetes: The Randomized Head-to-Head BRIGHT Trial.
Julio Rosenstock, Alice Cheng, Robert Ritzel, Zsolt Bosnyak, Christine Devisme, Anna M G Cali, Jochen Sieber, Peter Stella, Xiangling Wang, Juan P Frías,[...]. Diabetes Care 2018
Julio Rosenstock, Alice Cheng, Robert Ritzel, Zsolt Bosnyak, Christine Devisme, Anna M G Cali, Jochen Sieber, Peter Stella, Xiangling Wang, Juan P Frías,[...]. Diabetes Care 2018
32
Insulin degludec versus insulin glargine in insulin-naive patients with type 2 diabetes: a 1-year, randomized, treat-to-target trial (BEGIN Once Long).
Bernard Zinman, Athena Philis-Tsimikas, Bertrand Cariou, Yehuda Handelsman, Helena W Rodbard, Thue Johansen, Lars Endahl, Chantal Mathieu. Diabetes Care 2012
Bernard Zinman, Athena Philis-Tsimikas, Bertrand Cariou, Yehuda Handelsman, Helena W Rodbard, Thue Johansen, Lars Endahl, Chantal Mathieu. Diabetes Care 2012
28
Insulin degludec: four times lower pharmacodynamic variability than insulin glargine under steady-state conditions in type 1 diabetes.
T Heise, L Hermanski, L Nosek, A Feldman, S Rasmussen, H Haahr. Diabetes Obes Metab 2012
T Heise, L Hermanski, L Nosek, A Feldman, S Rasmussen, H Haahr. Diabetes Obes Metab 2012
27
New insulin glargine 300 U/ml compared with glargine 100 U/ml in insulin-naïve people with type 2 diabetes on oral glucose-lowering drugs: a randomized controlled trial (EDITION 3).
G B Bolli, M C Riddle, R M Bergenstal, M Ziemen, K Sestakauskas, H Goyeau, P D Home. Diabetes Obes Metab 2015
G B Bolli, M C Riddle, R M Bergenstal, M Ziemen, K Sestakauskas, H Goyeau, P D Home. Diabetes Obes Metab 2015
26
New insulin glargine 300 units/mL versus glargine 100 units/mL in people with type 2 diabetes using oral agents and basal insulin: glucose control and hypoglycemia in a 6-month randomized controlled trial (EDITION 2).
Hannele Yki-Järvinen, Richard Bergenstal, Monika Ziemen, Marek Wardecki, Isabel Muehlen-Bartmer, Emmanuelle Boelle, Matthew C Riddle. Diabetes Care 2014
Hannele Yki-Järvinen, Richard Bergenstal, Monika Ziemen, Marek Wardecki, Isabel Muehlen-Bartmer, Emmanuelle Boelle, Matthew C Riddle. Diabetes Care 2014
25
Ultra-long-acting insulin degludec has a flat and stable glucose-lowering effect in type 2 diabetes.
T Heise, L Nosek, S G Bøttcher, H Hastrup, H Haahr. Diabetes Obes Metab 2012
T Heise, L Nosek, S G Bøttcher, H Hastrup, H Haahr. Diabetes Obes Metab 2012
24
New insulin glargine 300 units/mL versus glargine 100 units/mL in people with type 2 diabetes using basal and mealtime insulin: glucose control and hypoglycemia in a 6-month randomized controlled trial (EDITION 1).
Matthew C Riddle, Geremia B Bolli, Monika Ziemen, Isabel Muehlen-Bartmer, Florence Bizet, Philip D Home. Diabetes Care 2014
Matthew C Riddle, Geremia B Bolli, Monika Ziemen, Isabel Muehlen-Bartmer, Florence Bizet, Philip D Home. Diabetes Care 2014
23
Insulin degludec, an ultra-longacting basal insulin, versus insulin glargine in basal-bolus treatment with mealtime insulin aspart in type 2 diabetes (BEGIN Basal-Bolus Type 2): a phase 3, randomised, open-label, treat-to-target non-inferiority trial.
Alan J Garber, Allen B King, Stefano Del Prato, Seamus Sreenan, Mustafa K Balci, Manuel Muñoz-Torres, Julio Rosenstock, Lars A Endahl, Ann Marie Ocampo Francisco, Priscilla Hollander. Lancet 2012
Alan J Garber, Allen B King, Stefano Del Prato, Seamus Sreenan, Mustafa K Balci, Manuel Muñoz-Torres, Julio Rosenstock, Lars A Endahl, Ann Marie Ocampo Francisco, Priscilla Hollander. Lancet 2012
22
The efficacy and safety of insulin degludec given in variable once-daily dosing intervals compared with insulin glargine and insulin degludec dosed at the same time daily: a 26-week, randomized, open-label, parallel-group, treat-to-target trial in individuals with type 2 diabetes.
Luigi Meneghini, Stephen L Atkin, Stephen C L Gough, Itamar Raz, Lawrence Blonde, Marina Shestakova, Stephen Bain, Thue Johansen, Kamilla Begtrup, Kåre I Birkeland. Diabetes Care 2013
Luigi Meneghini, Stephen L Atkin, Stephen C L Gough, Itamar Raz, Lawrence Blonde, Marina Shestakova, Stephen Bain, Thue Johansen, Kamilla Begtrup, Kåre I Birkeland. Diabetes Care 2013
20
Management of Hyperglycemia in Type 2 Diabetes, 2018. A Consensus Report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD).
Melanie J Davies, David A D'Alessio, Judith Fradkin, Walter N Kernan, Chantal Mathieu, Geltrude Mingrone, Peter Rossing, Apostolos Tsapas, Deborah J Wexler, John B Buse. Diabetes Care 2018
Melanie J Davies, David A D'Alessio, Judith Fradkin, Walter N Kernan, Chantal Mathieu, Geltrude Mingrone, Peter Rossing, Apostolos Tsapas, Deborah J Wexler, John B Buse. Diabetes Care 2018
20
Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes.
Steven P Marso, Gilbert H Daniels, Kirstine Brown-Frandsen, Peter Kristensen, Johannes F E Mann, Michael A Nauck, Steven E Nissen, Stuart Pocock, Neil R Poulter, Lasse S Ravn,[...]. N Engl J Med 2016
Steven P Marso, Gilbert H Daniels, Kirstine Brown-Frandsen, Peter Kristensen, Johannes F E Mann, Michael A Nauck, Steven E Nissen, Stuart Pocock, Neil R Poulter, Lasse S Ravn,[...]. N Engl J Med 2016
18
Hypoglycemia and diabetes: a report of a workgroup of the American Diabetes Association and the Endocrine Society.
Elizabeth R Seaquist, John Anderson, Belinda Childs, Philip Cryer, Samuel Dagogo-Jack, Lisa Fish, Simon R Heller, Henry Rodriguez, James Rosenzweig, Robert Vigersky. Diabetes Care 2013
Elizabeth R Seaquist, John Anderson, Belinda Childs, Philip Cryer, Samuel Dagogo-Jack, Lisa Fish, Simon R Heller, Henry Rodriguez, James Rosenzweig, Robert Vigersky. Diabetes Care 2013
18
Design of the novel protraction mechanism of insulin degludec, an ultra-long-acting basal insulin.
Ib Jonassen, Svend Havelund, Thomas Hoeg-Jensen, Dorte Bjerre Steensgaard, Per-Olof Wahlund, Ulla Ribel. Pharm Res 2012
Ib Jonassen, Svend Havelund, Thomas Hoeg-Jensen, Dorte Bjerre Steensgaard, Per-Olof Wahlund, Ulla Ribel. Pharm Res 2012
18
Insulin degludec: Lower day-to-day and within-day variability in pharmacodynamic response compared with insulin glargine 300 U/mL in type 1 diabetes.
Tim Heise, Marianne Nørskov, Leszek Nosek, Kadriye Kaplan, Susanne Famulla, Hanne L Haahr. Diabetes Obes Metab 2017
Tim Heise, Marianne Nørskov, Leszek Nosek, Kadriye Kaplan, Susanne Famulla, Hanne L Haahr. Diabetes Obes Metab 2017
23
Glycaemic control and hypoglycaemia with new insulin glargine 300 U/ml versus insulin glargine 100 U/ml in people with type 2 diabetes using basal insulin and oral antihyperglycaemic drugs: the EDITION 2 randomized 12-month trial including 6-month extension.
H Yki-Järvinen, R M Bergenstal, G B Bolli, M Ziemen, M Wardecki, I Muehlen-Bartmer, M Maroccia, M C Riddle. Diabetes Obes Metab 2015
H Yki-Järvinen, R M Bergenstal, G B Bolli, M Ziemen, M Wardecki, I Muehlen-Bartmer, M Maroccia, M C Riddle. Diabetes Obes Metab 2015
22
10-year follow-up of intensive glucose control in type 2 diabetes.
Rury R Holman, Sanjoy K Paul, M Angelyn Bethel, David R Matthews, H Andrew W Neil. N Engl J Med 2008
Rury R Holman, Sanjoy K Paul, M Angelyn Bethel, David R Matthews, H Andrew W Neil. N Engl J Med 2008
18
Low-volume insulin degludec 200 units/ml once daily improves glycemic control similarly to insulin glargine with a low risk of hypoglycemia in insulin-naive patients with type 2 diabetes: a 26-week, randomized, controlled, multinational, treat-to-target trial: the BEGIN LOW VOLUME trial.
Stephen C L Gough, Anuj Bhargava, Rajeev Jain, Henriette Mersebach, Søren Rasmussen, Richard M Bergenstal. Diabetes Care 2013
Stephen C L Gough, Anuj Bhargava, Rajeev Jain, Henriette Mersebach, Søren Rasmussen, Richard M Bergenstal. Diabetes Care 2013
17
Severe hypoglycemia and risks of vascular events and death.
Sophia Zoungas, Anushka Patel, John Chalmers, Bastiaan E de Galan, Qiang Li, Laurent Billot, Mark Woodward, Toshiharu Ninomiya, Bruce Neal, Stephen MacMahon,[...]. N Engl J Med 2010
Sophia Zoungas, Anushka Patel, John Chalmers, Bastiaan E de Galan, Qiang Li, Laurent Billot, Mark Woodward, Toshiharu Ninomiya, Bruce Neal, Stephen MacMahon,[...]. N Engl J Med 2010
16
Patient-level meta-analysis of the EDITION 1, 2 and 3 studies: glycaemic control and hypoglycaemia with new insulin glargine 300 U/ml versus glargine 100 U/ml in people with type 2 diabetes.
R Ritzel, R Roussel, G B Bolli, L Vinet, C Brulle-Wohlhueter, S Glezer, H Yki-Järvinen. Diabetes Obes Metab 2015
R Ritzel, R Roussel, G B Bolli, L Vinet, C Brulle-Wohlhueter, S Glezer, H Yki-Järvinen. Diabetes Obes Metab 2015
16
New insulin glargine 300 U/ml versus glargine 100 U/ml in Japanese people with type 2 diabetes using basal insulin and oral antihyperglycaemic drugs: glucose control and hypoglycaemia in a randomized controlled trial (EDITION JP 2).
Y Terauchi, M Koyama, X Cheng, Y Takahashi, M C Riddle, G B Bolli, T Hirose. Diabetes Obes Metab 2016
Y Terauchi, M Koyama, X Cheng, Y Takahashi, M C Riddle, G B Bolli, T Hirose. Diabetes Obes Metab 2016
19
Morning administration of 0.4U/kg/day insulin glargine 300U/mL provides less fluctuating 24-hour pharmacodynamics and more even pharmacokinetic profiles compared with insulin degludec 100U/mL in type 1 diabetes.
T S Bailey, J Pettus, R Roussel, W Schmider, M Maroccia, N Nassr, O Klein, G B Bolli, R Dahmen. Diabetes Metab 2018
T S Bailey, J Pettus, R Roussel, W Schmider, M Maroccia, N Nassr, O Klein, G B Bolli, R Dahmen. Diabetes Metab 2018
25
New insulin glargine 300 Units · mL-1 provides a more even activity profile and prolonged glycemic control at steady state compared with insulin glargine 100 Units · mL-1.
Reinhard H A Becker, Raphael Dahmen, Karin Bergmann, Anne Lehmann, Thomas Jax, Tim Heise. Diabetes Care 2015
Reinhard H A Becker, Raphael Dahmen, Karin Bergmann, Anne Lehmann, Thomas Jax, Tim Heise. Diabetes Care 2015
15
One-year sustained glycaemic control and less hypoglycaemia with new insulin glargine 300 U/ml compared with 100 U/ml in people with type 2 diabetes using basal plus meal-time insulin: the EDITION 1 12-month randomized trial, including 6-month extension.
M C Riddle, H Yki-Järvinen, G B Bolli, M Ziemen, I Muehlen-Bartmer, S Cissokho, P D Home. Diabetes Obes Metab 2015
M C Riddle, H Yki-Järvinen, G B Bolli, M Ziemen, I Muehlen-Bartmer, S Cissokho, P D Home. Diabetes Obes Metab 2015
18
Basal insulin and cardiovascular and other outcomes in dysglycemia.
Hertzel C Gerstein, Jackie Bosch, Gilles R Dagenais, Rafael Díaz, Hyejung Jung, Aldo P Maggioni, Janice Pogue, Jeffrey Probstfield, Ambady Ramachandran, Matthew C Riddle,[...]. N Engl J Med 2012
Hertzel C Gerstein, Jackie Bosch, Gilles R Dagenais, Rafael Díaz, Hyejung Jung, Aldo P Maggioni, Janice Pogue, Jeffrey Probstfield, Ambady Ramachandran, Matthew C Riddle,[...]. N Engl J Med 2012
15
Comparison of the pharmacokinetic and pharmacodynamic profiles of insulin degludec and insulin glargine.
Tim Heise, Ulrike Hövelmann, Leszek Nosek, Lidia Hermanski, Susanne G Bøttcher, Hanne Haahr. Expert Opin Drug Metab Toxicol 2015
Tim Heise, Ulrike Hövelmann, Leszek Nosek, Lidia Hermanski, Susanne G Bøttcher, Hanne Haahr. Expert Opin Drug Metab Toxicol 2015
17
Effects of intensive glucose lowering in type 2 diabetes.
Hertzel C Gerstein, Michael E Miller, Robert P Byington, David C Goff, J Thomas Bigger, John B Buse, William C Cushman, Saul Genuth, Faramarz Ismail-Beigi, Richard H Grimm,[...]. N Engl J Med 2008
Hertzel C Gerstein, Michael E Miller, Robert P Byington, David C Goff, J Thomas Bigger, John B Buse, William C Cushman, Saul Genuth, Faramarz Ismail-Beigi, Richard H Grimm,[...]. N Engl J Med 2008
14
A review of the pharmacological properties of insulin degludec and their clinical relevance.
Hanne Haahr, Tim Heise. Clin Pharmacokinet 2014
Hanne Haahr, Tim Heise. Clin Pharmacokinet 2014
14
New Insulin Glargine 300 Units/mL Versus Glargine 100 Units/mL in People With Type 1 Diabetes: A Randomized, Phase 3a, Open-Label Clinical Trial (EDITION 4).
Philip D Home, Richard M Bergenstal, Geremia B Bolli, Monika Ziemen, Maria Rojeski, Melanie Espinasse, Matthew C Riddle. Diabetes Care 2015
Philip D Home, Richard M Bergenstal, Geremia B Bolli, Monika Ziemen, Maria Rojeski, Melanie Espinasse, Matthew C Riddle. Diabetes Care 2015
14
Clinical outcomes in real-world patients with type 2 diabetes switching from first- to second-generation basal insulin analogues: Comparative effectiveness of insulin glargine 300 units/mL and insulin degludec in the DELIVER D+ cohort study.
Sean D Sullivan, Timothy S Bailey, Ronan Roussel, Fang Liz Zhou, Zsolt Bosnyak, Ronald Preblick, Jukka Westerbacka, Rishab A Gupta, Lawrence Blonde. Diabetes Obes Metab 2018
Sean D Sullivan, Timothy S Bailey, Ronan Roussel, Fang Liz Zhou, Zsolt Bosnyak, Ronald Preblick, Jukka Westerbacka, Rishab A Gupta, Lawrence Blonde. Diabetes Obes Metab 2018
30
Glucose control and vascular complications in veterans with type 2 diabetes.
William Duckworth, Carlos Abraira, Thomas Moritz, Domenic Reda, Nicholas Emanuele, Peter D Reaven, Franklin J Zieve, Jennifer Marks, Stephen N Davis, Rodney Hayward,[...]. N Engl J Med 2009
William Duckworth, Carlos Abraira, Thomas Moritz, Domenic Reda, Nicholas Emanuele, Peter D Reaven, Franklin J Zieve, Jennifer Marks, Stephen N Davis, Rodney Hayward,[...]. N Engl J Med 2009
13
Insulin degludec versus insulin glargine in type 1 and type 2 diabetes mellitus: a meta-analysis of endpoints in phase 3a trials.
Jiten Vora, Torsten Christensen, Azhar Rana, Steve C Bain. Diabetes Ther 2014
Jiten Vora, Torsten Christensen, Azhar Rana, Steve C Bain. Diabetes Ther 2014
19
Impact of the mode of protraction of basal insulin therapies on their pharmacokinetic and pharmacodynamic properties and resulting clinical outcomes.
Tim Heise, Chantal Mathieu. Diabetes Obes Metab 2017
Tim Heise, Chantal Mathieu. Diabetes Obes Metab 2017
20
Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes.
Steven P Marso, Stephen C Bain, Agostino Consoli, Freddy G Eliaschewitz, Esteban Jódar, Lawrence A Leiter, Ildiko Lingvay, Julio Rosenstock, Jochen Seufert, Mark L Warren,[...]. N Engl J Med 2016
Steven P Marso, Stephen C Bain, Agostino Consoli, Freddy G Eliaschewitz, Esteban Jódar, Lawrence A Leiter, Ildiko Lingvay, Julio Rosenstock, Jochen Seufert, Mark L Warren,[...]. N Engl J Med 2016
13
Comparison of insulin degludec with insulin glargine in insulin-naive subjects with Type 2 diabetes: a 2-year randomized, treat-to-target trial.
H W Rodbard, B Cariou, B Zinman, Y Handelsman, A Philis-Tsimikas, T V Skjøth, A Rana, C Mathieu. Diabet Med 2013
H W Rodbard, B Cariou, B Zinman, Y Handelsman, A Philis-Tsimikas, T V Skjøth, A Rana, C Mathieu. Diabet Med 2013
20
A comparative effectiveness study of degludec and insulin glargine 300 U/mL in insulin-naïve patients with type 2 diabetes.
Joseph Tibaldi, Martin Hadley-Brown, Andreas Liebl, Steffen Haldrup, Viktor Sandberg, Michael L Wolden, Helena W Rodbard. Diabetes Obes Metab 2019
Joseph Tibaldi, Martin Hadley-Brown, Andreas Liebl, Steffen Haldrup, Viktor Sandberg, Michael L Wolden, Helena W Rodbard. Diabetes Obes Metab 2019
50
The treat-to-target trial: randomized addition of glargine or human NPH insulin to oral therapy of type 2 diabetic patients.
Matthew C Riddle, Julio Rosenstock, John Gerich. Diabetes Care 2003
Matthew C Riddle, Julio Rosenstock, John Gerich. Diabetes Care 2003
13
A European, multicentre, retrospective, non-interventional study (EU-TREAT) of the effectiveness of insulin degludec after switching basal insulin in a population with type 1 or type 2 diabetes.
Thorsten Siegmund, Nikolaos Tentolouris, Søren T Knudsen, Annunziata Lapolla, Rudolf Prager, Tra-Mi Phan, Michael L Wolden, Bernd Schultes. Diabetes Obes Metab 2018
Thorsten Siegmund, Nikolaos Tentolouris, Søren T Knudsen, Annunziata Lapolla, Rudolf Prager, Tra-Mi Phan, Michael L Wolden, Bernd Schultes. Diabetes Obes Metab 2018
44
12
A comparison of the steady-state pharmacokinetic and pharmacodynamic profiles of 100 and 200 U/mL formulations of ultra-long-acting insulin degludec.
Stefan Korsatko, Sigrid Deller, Gerd Koehler, Julia K Mader, Katharina Neubauer, Charlotte L Adrian, Henrik Thomsen, Hanne Haahr, Thomas R Pieber. Clin Drug Investig 2013
Stefan Korsatko, Sigrid Deller, Gerd Koehler, Julia K Mader, Katharina Neubauer, Charlotte L Adrian, Henrik Thomsen, Hanne Haahr, Thomas R Pieber. Clin Drug Investig 2013
18
Efficacy and safety of insulin degludec in a flexible dosing regimen vs insulin glargine in patients with type 1 diabetes (BEGIN: Flex T1): a 26-week randomized, treat-to-target trial with a 26-week extension.
Chantal Mathieu, Priscilla Hollander, Bresta Miranda-Palma, John Cooper, Edward Franek, David Russell-Jones, Jens Larsen, Søren Can Tamer, Stephen C Bain. J Clin Endocrinol Metab 2013
Chantal Mathieu, Priscilla Hollander, Bresta Miranda-Palma, John Cooper, Edward Franek, David Russell-Jones, Jens Larsen, Søren Can Tamer, Stephen C Bain. J Clin Endocrinol Metab 2013
12
Insulin degludec compared with insulin glargine in insulin-naïve patients with type 2 diabetes: A 26-week, randomized, controlled, Pan-Asian, treat-to-target trial.
Yukiko Onishi, Yasuhiko Iwamoto, Soon Jib Yoo, Per Clauson, Søren C Tamer, Sungwoo Park. J Diabetes Investig 2013
Yukiko Onishi, Yasuhiko Iwamoto, Soon Jib Yoo, Per Clauson, Søren C Tamer, Sungwoo Park. J Diabetes Investig 2013
15
Better glycaemic control and less hypoglycaemia with insulin glargine 300 U/mL vs glargine 100 U/mL: 1-year patient-level meta-analysis of the EDITION clinical studies in people with type 2 diabetes.
Robert Ritzel, Ronan Roussel, Andrea Giaccari, Jiten Vora, Claire Brulle-Wohlhueter, Hannele Yki-Järvinen. Diabetes Obes Metab 2018
Robert Ritzel, Ronan Roussel, Andrea Giaccari, Jiten Vora, Claire Brulle-Wohlhueter, Hannele Yki-Järvinen. Diabetes Obes Metab 2018
25
Rates and predictors of hypoglycaemia in 27 585 people from 24 countries with insulin-treated type 1 and type 2 diabetes: the global HAT study.
K Khunti, S Alsifri, R Aronson, M Cigrovski Berković, C Enters-Weijnen, T Forsén, G Galstyan, P Geelhoed-Duijvestijn, M Goldfracht, H Gydesen,[...]. Diabetes Obes Metab 2016
K Khunti, S Alsifri, R Aronson, M Cigrovski Berković, C Enters-Weijnen, T Forsén, G Galstyan, P Geelhoed-Duijvestijn, M Goldfracht, H Gydesen,[...]. Diabetes Obes Metab 2016
11
Insulin adherence behaviours and barriers in the multinational Global Attitudes of Patients and Physicians in Insulin Therapy study.
M Peyrot, A H Barnett, L F Meneghini, P-M Schumm-Draeger. Diabet Med 2012
M Peyrot, A H Barnett, L F Meneghini, P-M Schumm-Draeger. Diabet Med 2012
11
Comparison of Insulin Glargine 300 Units/mL and 100 Units/mL in Adults With Type 1 Diabetes: Continuous Glucose Monitoring Profiles and Variability Using Morning or Evening Injections.
Richard M Bergenstal, Timothy S Bailey, David Rodbard, Monika Ziemen, Hailing Guo, Isabel Muehlen-Bartmer, Andrew J Ahmann. Diabetes Care 2017
Richard M Bergenstal, Timothy S Bailey, David Rodbard, Monika Ziemen, Hailing Guo, Isabel Muehlen-Bartmer, Andrew J Ahmann. Diabetes Care 2017
15
Insulin degludec, an ultra-longacting basal insulin, versus insulin glargine in basal-bolus treatment with mealtime insulin aspart in type 1 diabetes (BEGIN Basal-Bolus Type 1): a phase 3, randomised, open-label, treat-to-target non-inferiority trial.
Simon Heller, John Buse, Miles Fisher, Satish Garg, Michel Marre, Ludwig Merker, Eric Renard, David Russell-Jones, Areti Philotheou, Ann Marie Ocampo Francisco,[...]. Lancet 2012
Simon Heller, John Buse, Miles Fisher, Satish Garg, Michel Marre, Ludwig Merker, Eric Renard, David Russell-Jones, Areti Philotheou, Ann Marie Ocampo Francisco,[...]. Lancet 2012
11
Long-acting insulin analogues versus NPH insulin (human isophane insulin) for type 2 diabetes mellitus.
K Horvath, K Jeitler, A Berghold, S H Ebrahim, T W Gratzer, J Plank, T Kaiser, T R Pieber, A Siebenhofer. Cochrane Database Syst Rev 2007
K Horvath, K Jeitler, A Berghold, S H Ebrahim, T W Gratzer, J Plank, T Kaiser, T R Pieber, A Siebenhofer. Cochrane Database Syst Rev 2007
11
Co-cited is the co-citation frequency, indicating how many articles cite the article together with the query article. Similarity is the co-citation as percentage of the times cited of the query article or the article in the search results, whichever is the lowest. These numbers are calculated for the last 100 citations when articles are cited more than 100 times.